IP Library Granted Patent US 10,583,105
Granted Patent B2
US 10,583,105 · App. 16/371,779 · Granted Mar 10, 2020

Compositions and methods for neuroprotection and treatment of neurodegeneration

Inventors: Mark C. Faulkner (Madison, TN); Donald W. Miller (Winnipeg, CA); Grant M. Hatch (Winnipeg, CA)
Assignee: Vireo Systems, Inc.
A61K31/197A61K31/221A61P25/00A61P25/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,105
App. No.
16/371,779
Granted
Mar 10, 2020
Kind
B2
Abstract

Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

Claims (22)

1. A method for preventing or reducing neurodegeneration in a human, comprising:

administering an effective amount of a composition comprising creatine hydrochloride to the human, wherein the human has the huntingtin gene mutation.

2. The method of claim 1 , wherein the effective amount comprises a daily dose of about 0.5 grams to about 20 grams.

3. The method of claim 2 , wherein the effective amount comprises a daily dose of about 10 grams to about 15 grams.

4. The method of claim 1 , wherein the composition is administered as a nutritional or dietary supplement or as a functional food.

5. The method of claim 1 , wherein the creatine hydrochloride is present in the composition in an amount of at least about 50 percent by weight of the composition.

6. The method of claim 1 , wherein the composition further comprises creatinine, creatine monohydrate, creatine ester, or combinations thereof.

7. The method of claim 1 , wherein the composition is administered in the form of a pill, tablet, capsule, or gel capsule.

8. A method for treating Huntington's disease, comprising:

administering an effective amount of creatine hydrochloride to a human suffering from Huntington's disease.

9. The method of claim 8 , wherein the effective amount comprises a daily dose of about 0.5 grams to about 20 grams.

10. The method of claim 8 , wherein the effective amount comprises a daily dose of about 2 grams to about 8 grams.

11. The method of claim 8 , wherein the creatine hydrochloride is administered in combination with creatinine, creatine monohydrate, creatine ester, or combinations thereof.

12. The method of claim 8 , wherein the creatine hydrochloride is administered in the form of a liquid, gel, or powder.

13. The method of claim 8 , wherein after the administering step, spare respiratory capacity of mitochondria in lymphoblast cells increases by at least about 60 percent.

14. The method of claim 8 , wherein after the administering step, total ATP turnover of mitochondria in lymphoblast cells increases by at least about 75 percent.

15. A method of treating Huntington's disease or Parkinson's disease in a human, comprising:

administering to the human a daily dose of a composition comprising creatine hydrochloride.

16. The method of claim 15 , wherein the daily dose comprises about 0.5 grams to about 20 grams of creatine hydrochloride.

17. The method of claim 15 , wherein the daily dose comprises about 2 grams to about 8 grams of creatine hydrochloride.

18. The method of claim 15 , wherein, after the step of administering, levels of diacylglycerol acyltransferase 2 activity in lymphoblast cells increases by at least about 10 percent.

19. The method of claim 15 , wherein the creatine hydrochloride is present in the composition in an amount of at least about 75 percent by weight.

Assignments (2)
SECURITY INTEREST Recorded Aug 21, 2020
From: VIREO SYSTEMS, INC.; FAULKNER, MARK C
To: FIRSTBANK
Reel/Frame 053579/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: FAULKNER, MARK C.; MILLER, DONALD W.; HATCH, GRANT M.
To: VIREO SYSTEMS, INC.
Reel/Frame 048757/0247 →